Skip to content

Author

K. Pietiläinen

We have 6 of 360 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Disentangling direct and weight-mediated effects of physical activity on health-related quality of life in a 12-month real-world digital lifestyle intervention

To examine whether participation in a 12-month digital lifestyle program was associated with increased physical activity and whether physical activity was associated with health-related quality of life (HRQoL) independently of weight loss. Self-reported weight and height were used to calculate body mass index (BMI). Ph...

Isabel McCann, A. Joki, L. Suojanen et al. · 0 citations
Open access Oct 2026

Integration of single cell omics with biobank data discovers allele-specific trans effects of SREBF1 on adipocyte expression of nearly 100 genes

The heritability of epigenetic sites around SAT adipocyte marker genes is enriched for abdominal obesity, and that these cell-type markers are also enriched for central pathways of adipocyte function, indicating widespread cell-type level cis-type level trans effects on highly common CMDs.

M. G. Sukhatme, A. Kar, Seung Hyuk T. Lee et al. · 0 citations
Sep 2026

Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.

BACKGROUND Petrelintide is a novel, long-acting amylin analogue being developed for long-term treatment of obesity, leveraging a mechanism of action distinct from incretin-based treatments. This phase 2 trial aimed to evaluate the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity....

W. T. Garvey, J. Ard, L. Connery et al. · 1 citation
Oct 2026

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

BACKGROUND For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits. Survodutide is an investigational gluc...

Sean Wharton, C. L. le Roux, E. Startseva et al. · 0 citations
Open access Sep 2026

Genome-wide association meta-analysis of eating behavior traits revealed one susceptibility locus for emotional eating.

A meta-GWAS with seven studies of European ancestry identified for the first time a robust chromosomal region associated with emotional eating in seven studies, supporting the hypothesis that shared genetic factors may influence both eating behavior traits and obesity risk.

M. Muntaner, K. Horn, B. de Lauzon-Guillain et al. · 0 citations
Open access Aug 2026

Longitudinal associations of depressive and burnout symptoms with eating behavior and physical activity in occupational health clients with obesity

Findings highlight the interplay between mental health, eating, and physical activity, suggesting that addressing psychological distress in behavior change programs may improve outcomes for individuals with elevated depression and burnout.

Siniriikka A. Männistö, Joona Muotka, L. Suojanen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.